SG11201910096RA - Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use - Google Patents

Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Info

Publication number
SG11201910096RA
SG11201910096RA SG11201910096RA SG11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA
Authority
SG
Singapore
Prior art keywords
international
boost
adimab
lebanon
lucent
Prior art date
Application number
Other languages
English (en)
Inventor
Laura M Walker
Robert Pejchal
Eric Krauland
Maximiliano Vasquez
Monica Wai Ling Leung
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of SG11201910096RA publication Critical patent/SG11201910096RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201910096R 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use SG11201910096RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762503315P 2017-05-08 2017-05-08
PCT/US2018/031705 WO2018208864A1 (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Publications (1)

Publication Number Publication Date
SG11201910096RA true SG11201910096RA (en) 2019-11-28

Family

ID=64104990

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912494TA SG10201912494TA (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201910096R SG11201910096RA (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912494TA SG10201912494TA (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Country Status (11)

Country Link
US (2) US11542330B2 (ja)
EP (1) EP3621641A4 (ja)
JP (3) JP7393207B2 (ja)
KR (1) KR20200053437A (ja)
CN (1) CN110913895B (ja)
AU (1) AU2018266711A1 (ja)
BR (1) BR112019023111A2 (ja)
CA (1) CA3062825A1 (ja)
MX (1) MX2019013184A (ja)
SG (2) SG10201912494TA (ja)
WO (1) WO2018208864A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3973000A4 (en) * 2019-06-07 2023-09-06 Adimab, LLC HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHODS OF GENERATION AND USE THEREOF
AU2020287384A1 (en) * 2019-06-07 2021-11-11 Adimab, Llc Engineered pH-dependent anti-CD3 antibodies, and methods for their generation and use
US20210087271A1 (en) * 2019-09-20 2021-03-25 Adimab, Llc Fc variants with reduced effector function
CA3164818A1 (en) * 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
CN115052897A (zh) * 2020-01-28 2022-09-13 普洛迈博生物技术公司 PLAP-CD3ε双特异性抗体
IL297701A (en) * 2020-04-27 2022-12-01 Twist Bioscience Corp Variable libraries of nucleic acids for the coronavirus
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
US20230374162A1 (en) * 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
CN114539415B (zh) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
CN112698044B (zh) * 2021-03-23 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 靶向治疗后免疫状态评价装置及方法
CA3234068A1 (en) * 2021-10-07 2023-04-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
CN118076387A (zh) * 2021-10-08 2024-05-24 艾贝乐医药科技有限公司 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法
CN114573705B (zh) * 2022-03-17 2024-05-14 杭州师范大学 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用
CN114605560B (zh) * 2022-03-30 2024-02-20 江苏蒙彼利生物科技有限公司 一种car-nk细胞及其制备方法与应用
CN116925232A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 靶向ceacam和cd3的多特异性抗体及其用途
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455127T1 (de) * 2003-05-31 2010-01-15 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
US9180186B2 (en) * 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
US8846042B2 (en) * 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
SG10201702396QA (en) * 2012-03-28 2017-04-27 Sanofi Sa Antibodies to bradykinin b1 receptor ligands
DK3083689T3 (da) * 2013-12-17 2020-08-03 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3

Also Published As

Publication number Publication date
MX2019013184A (es) 2020-02-07
RU2019139334A3 (ja) 2021-08-25
EP3621641A1 (en) 2020-03-18
AU2018266711A1 (en) 2019-11-28
JP7393207B2 (ja) 2023-12-06
JP2023014324A (ja) 2023-01-26
CN110913895B (zh) 2024-04-02
JP2020518650A (ja) 2020-06-25
KR20200053437A (ko) 2020-05-18
US20230151097A1 (en) 2023-05-18
EP3621641A4 (en) 2021-03-03
BR112019023111A2 (pt) 2020-07-28
JP2024032937A (ja) 2024-03-12
SG10201912494TA (en) 2020-02-27
US11542330B2 (en) 2023-01-03
CN110913895A (zh) 2020-03-24
US20200190189A1 (en) 2020-06-18
CA3062825A1 (en) 2018-11-15
WO2018208864A1 (en) 2018-11-15
RU2019139334A (ru) 2021-06-09

Similar Documents

Publication Publication Date Title
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201811405QA (en) Improved differentiation method
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201804710TA (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201903340TA (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201808314QA (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin